Authors
Latest:
Kim A. Reiss Binder, MD, on the Potential of CAR Macrophages in Solid TumorsThe assistant professor of medicine at University of Pennsylvania Hospital stressed the importance of tumor sequencing.
Latest:
Two ACGT all-stars celebrated with ‘Oscars of Science’ awardCarl June, MD, and Michel Sadelain, MD, PhD, were recognized for their pioneering achievements in treating cancer.
Latest:
Ivan Horak, MD, on Early Clinical Efficacy of Allogeneic CD30.CAR EBVST Cell Therapy in LymphomasThe chief medical and scientific officer of Tessa Therapeutics discussed data from the BESTA and CHARIOT studies presented at ASH 2022.
Latest:
Advantages of Developing Platform-Agnostic Gene TherapiesThe chief executive officer of Rocket Pharmaceuticals, Gaurav Shah, MD, discussed the company’s ex-vivo and in-vivo gene therapy platforms.
Latest:
Everett Meyer, MD, PhD, on Reducing GvHD in Leukemia TreatmentThe assistant professor of medicine and pediatrics at Stanford University discussed updated data from 2 studies of Orca-T cell therapy.
Latest:
Matthew Gornet, MD, on Treating Degenerative Disc Disease With Cell TherapyThe spine surgeon from The Orthopedic Center of St. Louis discussed recent data on IDCT from the phase 1/2 DGX-A01 study.
Latest:
PJ Brooks, PhD, on Improved Newborn Screening, Non-Viral Gene Editing: New Frontiers for Neuromuscular DiseaseThe deputy director, Division of Rare Diseases Research Innovation, NCATS, NIH, discussed areas that the agency is targeting.
Latest:
Madeleine Powys, MBBS, on Lessons Learned With LibmeldyThe locum consultant of pediatric BMT and leukemia at Royal Manchester Children’s Hospital discussed the center’s experience in delivering the approved gene therapy to children with MLD.
Latest:
Farah Sheikh, PhD, on Preclinical Research on Arrhythmogenic Cardiomyopathy Gene Therapy LX2020The professor of medicine at University of California San Diego discussed promising preclinical findings she presented at the American Heart Association’s Scientific Sessions 2023.
Latest:
Deyaa Adib, MD, on Optimizing Manufacturing of Solid Tumor Cell TherapiesThe chief medical officer of Triumvira Immunologics discussed the company’s future plans.
Latest:
Christa Krupski, DO, MPH, on Reinfusion of Tisagenlecleucel in B-ALLThe hematologist/oncologist at Cincinnati Children’s discussed unfavorable outcomes with tisa-cel reinfusion in patients with B-cell acute lymphocytic leukemia.
Latest:
Managing Safety in Fitusiran Treatments of Hemophilia: Guy Young, MDThe director of the hemostasis and thrombosis program at Children’s Hospital Los Angeles discussed mitigation strategies in trials and clinic.
Latest:
Matthew D. Weitzman, PhD, and Matthew Charman, PhD, on Further Investigation of the Viral Reproduction ProcessThe investigators from Children’s Hospital of Philadelphia discussed the follow-up studies they are conducting in light of their recent findings regarding DNA virus replication.
Latest:
Raj Mehra, PhD, and Krishna Subramanian, PhD, on Parkinson Disease Gene Therapy Mouse StudiesMehra and Subramanian discussed preclinical safety studies with the gene therapy SLS-004 and plans for future research.
Latest:
Atul Malhotra, MD, PhD, on Treating Preterm Infants With Autologous Stem Cell TherapyThe head of the early neurodevelopment clinic at Monash Children's Hospital discussed clinical trials in the field of neonatal cell therapy.
Latest:
Raj Mehra, PhD, and Krishna Subramanian, PhD, on Parkinson Disease Gene Therapy Mouse StudiesMehra and Subramanian discussed preclinical safety studies with the gene therapy SLS-004 and plans for future research.
Latest:
Cell Therapy May Yield Deep Remissions in Multiple MyelomaIde-cel's March 2021 FDA approval marks a significant advance in relapsed/refractory multiple myeloma treatment.
Latest:
Making Antigen-Presenting Cells With Cell Squeeze TechnologyThe founder and chief executive officer of SQZ Biotech discussed the potential of their APC platform to treat a variety of tumors.
Latest:
Arnaud Lacoste, PhD, on AURN001‘s Immunomodulatory PropertiesThe chief scientific officer of Aurion Biotech discussed the properties of the cell therapy for corneal dystrophies, which was recently approved in Japan.
Latest:
Gene and Cell Therapy Approaches Hold Promise for Usher SyndromeIn honor of Usher Syndrome Awareness Day, CGTLive® interviewed Zheng-Yi Chen, DPhil, associate professor, Otolaryngology–Head and Neck Surgery, Harvard Medical School, about the current state of research in this rare disease.
Latest:
HSCT With Omidubicel Achieved Robust Immune Reconstitution and Lower Rates of Severe Infection Compared to UCB TransplantationExpert hematologist/oncologist Paul Szabolcs, MD, reviews positive data from a clinical trial comparing hematopoietic stem cell transplantation and omidubicel with standard cord blood transplantation.
Latest:
Aude Chapuis, MD, on Improving TCR T-Cell Therapies for Cancer TreatmentThe associate professor in the Translational Science and Therapeutics Division at Fred Hutch Cancer Center discussed her lab’s research on making TCR T-cell therapies more effective.
Latest:
Kyle Garland, PhD, on the Potential of mRNA-engineered iPSC-derived Cell Therapies for Solid TumorsThe senior scientist at Eterna Therapeutics discussed the company’s numerous presentations at ASGCT’s 2023 conference.
Latest:
MDA Care Centers and the Future of Gene Therapy in Neuromuscular DiseaseBarry J Byrne, MD, PhD, the chief medical advisor of MDA, also shared his thoughts on the 75th anniversary of the organization.
Latest:
Reducing Off-Target Effects of CAR T-Cell TherapiesEric von Hofe, PhD, president and chief operating officer of AffyImmune, discussed advantages of the Affinity tuning platform.
Latest:
Barry Paul, MD, on Managing CRS and ICANS in Patients Receiving CAR-T for CancerPaul discussed common symptoms and typical treatments for the 2 adverse events.
Latest:
Alice Zhou, MD, PhD, and Omar Butt, MD, PhD, on Surprising Associations With Neurotoxicity and Neurofilament LightThe medical oncologists at Washington University School of Medicine in St. Louis discussed surprising findings from their retrospective study.
Latest:
New Research Identifies Safe Harbors for Gene Editing TherapiesThe Genomics and Epigenetic Guided Safe Harbor mapper will aid in the future design of gene-editing therapies.
Latest:
Gene Therapy for Rare Diseases: Latest UpdatesKinnari Patel, PharmD, president and chief operating officer of Rocket Pharmaceuticals, discussed Rocket Pharma’s programs.
Latest:
Brian Shaffer, MD, on Promising Signs of Efficacy in Post-CAR-T NHL NK Cell TherapyThe assistant attending physician and bone marrow transplant specialist at Memorial Sloan Kettering Cancer Center discussed updated data on GDA-201 plus rituximab.
